Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Director · President & CEO | March 19, 2021 | March 23, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Voyager Therapeutics, Inc.
Report date March 19, 2021 · Filed March 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 322,375 |
Reported balance
After 2021-03-19 transaction · row 1
1 source rowRow 1 · 2021-03-19 · Grant · Acquired 80,000 · Balance 322,375 F1: Consists of shares of common stock issuable under an aggregate of 80,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, March 19, 2021. The RSU award vests over two years, with 1/2 of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and the remainder of the shares of common stock underlying the RSU award vesting on the two-year anniversary of such vesting commencement date, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of shares of common stock issuable under an aggregate of 80,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, March 19, 2021. The RSU award vests over two years, with 1/2 of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and the remainder of the shares of common stock underlying the RSU award vesting on the two-year anniversary of such vesting commencement date, subject to the Reporting Person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 19, 2021 Filed Mar 23, 2021 20:10 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-040304 · tm2110581-2_4seq1.xml · nonDerivative · entry 1 Turenne Andre · CIK 0001747102 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 322,375 F1 · shares: Consists of shares of common stock issuable under an aggregate of 80,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, March 19, 2021. The RSU award vests over two years, with 1/2 of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and the remainder of the shares of common stock underlying the RSU award vesting on the two-year anniversary of such vesting commencement date, subject to the Reporting Person's continued service. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:59 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 189,000 | $0.00 Strike: $7.33 | $0.00 |
DisclosureSEC source: 0001104659-21-025278 · tm217191-4_4seq1.xml · derivative · entry 2 Turenne Andre · CIK 0001747102 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,000 Underlying: Common Stock · 189,000 shares Expires 2031-02-16 F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 16, 2021. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 21:59 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 94,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-025278 · tm217191-4_4seq1.xml · nonDerivative · entry 1 Turenne Andre · CIK 0001747102 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,375 F1 · shares: Consists of shares of common stock issuable under an aggregate of 94,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 16, 2021. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 21:11 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 7,977 | $7.55 | $60,226.35 |
DisclosureSEC source: 0001104659-21-023993 · tm216891-4_4seq1.xml · nonDerivative · entry 1 Turenne Andre · CIK 0001747102 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,375 F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 10, 2021. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.12 to $7.65, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| January 12, 2021 Filed Jan 14, 2021 22:59 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 10,443 | $8.62 | $90,018.66 |
DisclosureSEC source: 0001104659-21-004321 · tm213214-2_4seq1.xml · nonDerivative · entry 1 Turenne Andre · CIK 0001747102 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,352 F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 11, 2021. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.45 to $8.75, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:16 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 162,500 | $0.00 Strike: $12.96 | $0.00 |
DisclosureSEC source: 0001104659-20-019448 · a4.xml · derivative · entry 2 Turenne Andre · CIK 0001747102 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 162,500 shares Expires 2030-02-10 F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 10, 2020. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 23:16 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 81,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-019448 · a4.xml · nonDerivative · entry 1 Turenne Andre · CIK 0001747102 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,795 F1 · shares: Consists of shares of common stock issuable under an aggregate of 81,250 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 10, 2020. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| January 21, 2020 Filed Jan 29, 2020 22:26 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | SaleCommon Stock | 10,705 | $13.36 | $143,018.80 |
DisclosureSEC source: 0001104659-20-008187 · a4.xml · nonDerivative · entry 1 Turenne Andre · CIK 0001747102 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,545 F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 11, 2020. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.15 to $13.77, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| January 11, 2019 Filed Jan 18, 2019 02:05 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 192,500 | $0.00 Strike: $9.10 | $0.00 |
DisclosureSEC source: 0001104659-19-002349 · a4.xml · derivative · entry 2 Turenne Andre · CIK 0001747102 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,500 Underlying: Common Stock · 192,500 shares Expires 2029-01-11 F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, January 11, 2019. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| January 11, 2019 Filed Jan 18, 2019 02:05 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantCommon Stock | 96,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-002349 · a4.xml · nonDerivative · entry 1 Turenne Andre · CIK 0001747102 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,250 F1 · shares: Consists of shares of common stock issuable under an aggregate of 96,250 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, January 11, 2019. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 21:56 UTC | Voyager Therapeutics, Inc. VYGR · Entity 6271 | GrantStock Option (Right to Buy) · Derivative | 650,000 | $0.00 Strike: $18.03 | $0.00 |
DisclosureSEC source: 0001104659-18-045813 · a4.xml · derivative · entry 1 Turenne Andre · CIK 0001747102 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 650,000 Underlying: Common Stock · 650,000 shares Expires 2028-07-16 F1 · derivative.exercise_date: This stock option was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the "Company"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The vesting commencement date (the "Vesting Commencement Date") of the option is July 16, 2018. The option vests over four years, with 25% of the shares of common stock underlying the option vesting upon the one-year anniversary of the Vesting Commencement Date and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.